Replies to post #366724 on Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

You never responded to my post.

Because I have had other important things to do. Still, I respect questions. So, let me answer by asking a question. Are you sure Nasrat lied or might he have given investors an insight into what he knows?

It is easy to find some statement or apparent misstatement and ascribe a particular view depending on our cognition. What astute investors should recognize is that, on some occasions, management will provide unintended insights into what is going on. After all, we could look at what Nasrat said on the Q 2 2022 CC...

Partnerships. Do you see any new partnerships on the horizon? Yes, I do. There's always something on the horizon.

Sure he did...24 days later the Dexcel partnership was completed with the SEC filing.

Then there is this from the same CC...

SequestOx does not need to be reformulated. There's nothing wrong with the formulation.

The third question is did Elite lose interest in the opioid business?

Hell no. The answer to the first few questions, it's not that simple. Okay. And so our interest in opioids, one of many issues with opioids is the lawsuits. And granted the person who was referring to the defendant winning in the state of California, a judge ruled in favor of the pharmaceutical companies that they did not cause the opioid crisis. One lawsuit versus the 100 that's what lawsuit so far. So by the way, for example, if we were working on Oxy ER anti-abuse, if Pfizer did not. The profits from such a product will be high enough that I would be willing to take the risk. And I would launch at risk. And there are a few other things that I have already thought of that we do to mitigate that risk.

Please recognize that Nasrat is providing insight into what he is thinking, but he will not tell us what he is doing. Pay attention because these are the insights that CEOs can provide and I think it includes what he said about the LCI partnership. In fact, on that I will suggest the agreement will end before its termination date of March 5, 2024...particularly if Elite is working on a generic Concerta, a product LCI has been commercializing for some time.

Funny thing about business intel is that much can be found in open source material. I tell that to my audiences on every level - academic and professional. And that is a great place to end, as I have to prepare a keynote address to a group of business managers.